Question 1

What is the TechBio 100?

Accepted Answer

The TechBio 100 is a curated directory of the most active venture capital funds investing at the intersection of AI and biology. It tracks firms backing AI drug discovery, computational biology platforms, ML-driven diagnostics, bioinfrastructure, and medical devices, and is maintained by Atria Ventures with data powered by Harmonic.

Question 2

Who are the most active seed investors in AI and biology?

Accepted Answer

Specialist seed-stage funds writing first institutional checks in AI × Biology include Atria Ventures, Dimension Capital, KdT Ventures, Obvious Ventures, Cantos, and Amplify Partners. These funds are often the earliest signal that later-stage investors and pharma corporate-development teams follow into Series A and beyond.

Question 3

What categories do TechBio 100 funds invest in?

Accepted Answer

The TechBio 100 organizes funds across five focus areas: Platform Biology (computational biology platforms, synthetic biology, protein engineering), AI / ML Models for biology (foundation models, drug discovery AI, genomics AI), Diagnostics (molecular diagnostics, liquid biopsy, clinical decision support), Medical Devices (digital health hardware, surgical robotics, wearables), and Bio Infrastructure (lab automation, LIMS, CRO/CDMO platforms).

Question 4

How is the TechBio 100 maintained?

Accepted Answer

The list is curated by Atria Ventures using data powered by Harmonic, Pitchbook, SEC filings, and other proprietary sources. Every fund listed has announced at least two AI × Biology deals in the past 12 months and has raised a venture capital fund within the past three years per NVCA definitions.

Recently Announced Deals